Study Evaluating MYO-029 in Adult Muscular Dystrophy

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this phase I/II, multicenter, safety trial is to study MYO-029 in adult patients with muscular dystrophy.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Criteria

Inclusion Criteria:

• Written informed consent.

• Confirmed clinical and molecular diagnosis of Becker Muscular Dystrophy (BMD), Facioscapulohumeral Muscular Dystrophy (FSHD), or Limb-Girdle Muscular Dystrophy (LGMD)

• Independently ambulatory

Exclusion Criteria:

• Patients with certain clinical conditions

• Patients using steroids or other medications with the potential to affect muscle function

• History of sensitivity to monoclonal antibodies or protein pharmaceuticals

• Pregnant or lactating women.